Melinta Therapeutics
44 Whippany Rd, Suite 280
Morristown
New Jersey
07960
United States
Tel: n/a
Fax: n/a
Website: http://www.melinta.com/
Email: info@melinta.com
160 articles about Melinta Therapeutics
-
New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection
2/20/2024
Venatorx Pharmaceuticals, Melinta Therapeutics LLC (“Melinta”), and Menarini Group today announced that The New England Journal of Medicine (NEJM) published the results of the CERTAIN-1 Phase 3 clinical study of the investigational agent cefepime-taniborbactam for the treatment of adult patients with complicated urinary tract infections (cUTI) and acute pyelonephritis (AP), including those with bacteremia.
-
Melinta Therapeutics & Cidara Therapeutics Announce Publication of Pooled Data from Phase 3 Pivotal ReSTORE Trial
12/5/2023
Melinta Therapeutics & Cidara Therapeutics Announce Publication of Pooled Data from Phase 3 Pivotal ReSTORE Trial.
-
Melinta Therapeutics and Venatorx Pharmaceuticals Announce Licensing Agreement to Commercialize Cefepime-Taniborbactam in the U.S.
11/9/2023
Melinta Therapeutics LLC and Venatorx Pharmaceuticals, Inc., announced that they have entered into a License Agreement to facilitate a strategic partnership in the U.S. to commercialize cefepime-taniborbactam, a beta-lactam / beta-lactamase inhibitor combination antibiotic being developed for the treatment of complicated urinary tract infections and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in adults.
-
Melinta Therapeutics Announces Presentations of New Data on Infectious Disease Portfolio at IDWeek 2023
10/11/2023
Melinta Therapeutics, LLC announced today, the presentation of nine scientific presentations with data from its current anti-infective portfolio at Infectious Disease Week (IDWeek) 2023, taking place October 11-15, 2023, in Boston, MA.
-
Melinta Therapeutics Announces Expanded Reimbursement and Access for REZZAYO™ (rezafungin for injection)
10/2/2023
Melinta Therapeutics (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announced expanded reimbursement and access for REZZAYO™ (rezafungin for injection).
-
Melinta Therapeutics Announces Commercial Availability of REZZAYO™ (rezafungin for injection)
7/31/2023
Melinta Therapeutics, LLC today announced the availability of REZZAYO™ (rezafungin for injection), for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. REZZAYO is the first new treatment option approved for patients with candidemia and invasive candidiasis in over a decade.
-
Melinta Therapeutics Partners with BARDA to Advance Two FDA-Approved Antibiotics for Use in Pediatric Patients, and for Use Against Biothreat Pathogens
7/10/2023
Melinta Therapeutics, LLC announced today a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to advance two antibiotics currently FDA-approved for adults, BAXDELA® (delafloxacin) and VABOMERE® (meropenem and vaborbactam), for use in pediatrics.
-
Melinta Therapeutics and Xediton Pharmaceuticals Announce Licensing Agreement to Commercialize Anti-Infective Products in Canada
5/15/2023
Melinta Therapeutics, LLC (Melinta) and Xediton Pharmaceuticals Inc (Xediton) today announced they have entered into an exclusive commercialization and licensing agreement for BAXDELA ® (delafloxacin), KIMYRSA ® (oritavancin), ORBACTIV ® (oritavancin) and VABOMERE ® (meropenem and vaborbactam), four novel anti-infective products.
-
Cidara Therapeutics Receives $20 Million Milestone Payment Following FDA Approval of REZZAYO™
4/24/2023
Cidara Therapeutics, Inc. today announced receipt of a $20 million milestone payment from Melinta Therapeutics following the U.S. Food and Drug Administration (FDA) approval of REZZAYO™ (rezafungin for injection), a novel, once-weekly echinocandin antifungal approved for the treatment of candidemia and invasive candidiasis.
-
Wednesday, the FDA approved Cidara Therapeutics and Melinta Therapeutics’ Rezzayo (rezafungin) injection to treat candidemia and invasive candidiasis.
-
Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis
3/22/2023
Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Melinta Therapeutics, LLC today announced that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options.
-
Melinta Therapeutics & OptimizeRx Announce 2022 Innovate4Outcomes Event
11/30/2022
Melinta Therapeutics, LLC, a commercial-stage company providing innovative patient care therapies for acute and life-threatening illnesses, is partnering with OptimizeRx Corp. in an Innovate4Outcomes event - a healthcare design thinking-inspired event.
-
Cidara Therapeutics and Melinta Therapeutics Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet
11/28/2022
Cidara Therapeutics, Inc. (NASDAQ: CDTX) and Melinta Therapeutics, LLC today announced the peer-reviewed publication of data from the completed pivotal ReSTORE Phase 3 clinical trial evaluating the efficacy and safety of its once-weekly antifungal candidate rezafungin as a potential treatment for candidemia and invasive candidiasis.
-
Melinta Therapeutics Announces Presentation of New Data on Infectious Disease Portfolio at IDWeek 2022
10/18/2022
Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today, the presentation of nine scientific presentations with data from its current antibiotic portfolio at Infectious Disease Week (IDWeek) 2022, taking place October 19– 22, 2022, in Washington, D.C.
-
Melinta Therapeutics and Cidara Therapeutics Announce Licensing Agreement to Commercialize Rezafungin in the U.S.
7/27/2022
Melinta Therapeutics, LLC (“Melinta”) and Cidara Therapeutics (“Cidara”) today announced that they have entered into a License Agreement (the “Agreement”) to facilitate a strategic partnership to commercialize rezafungin, a novel, once-weekly echinocandin antifungal in the United States (U.S.).
-
Melinta Therapeutics Acquires U.S. Rights to TOPROL-XL® (metoprolol succinate) from New American Therapeutics
4/6/2022
Melinta Therapeutics, LLC (“Melinta”), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today that it has acquired the U.S. rights to TOPROL-XL® (metoprolol succinate) and its Authorized Generic (AG) through an agreement between Melinta and New American Therapeutics Inc.
-
Melinta Therapeutics Announces Appointment of Peter Piliero as Vice President of Medical Affairs
3/14/2022
Melinta Therapeutics announces the appointment of Dr. Peter Piliero as Vice President of Medical Affairs, effective today.
-
Melinta Therapeutics President and CEO Christine Ann Miller Elected to Board of Directors of Iveric Bio
1/6/2022
Melinta Therapeutics announced today that President and Chief Executive Officer Christine Ann Miller has been elected to the Board of Directors of IVERIC bio, Inc.
-
Melinta Therapeutics Announces Appointment of Doug Girgenti as Vice President of Drug Development
10/25/2021
Melinta Therapeutics, LLC (“Melinta”), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announces the appointment of Dr. Doug Girgenti as Vice President of Drug Development, effective today.
-
Melinta Therapeutics Announces Two Key Milestones Expanding Reimbursement and Access for KIMYRSA™ (oritavancin)
9/20/2021
Melinta Therapeutics today announced two important milestones for KIMYRSA™ (oritavancin), a lipoglycopeptide antibiotic that was launched in July.